EGFR and non-small cell lung carcinoma: There is an increasing number of evidence that show that the c-Met inhibitor exhibits a strong synergistic effect with EGFR inhibitors on EGFR-TKI resistant non-small cell lung cancer (NSCLC) cells harboring acquired c-Met gene amplification [8,9,10].